A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 91,700 shares of ALDX stock, worth $439,243. This represents 0.0% of its overall portfolio holdings.

Number of Shares
91,700
Previous 88,100 4.09%
Holding current value
$439,243
Previous $291,000 69.76%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.19 - $6.32 $142,232 - $281,789
44,587 Added 466.2%
54,151 $291,000
Q2 2024

Aug 14, 2024

SELL
$3.25 - $4.72 $148,473 - $215,628
-45,684 Reduced 82.69%
9,564 $31,000
Q1 2024

May 15, 2024

SELL
$2.77 - $4.22 $34,572 - $52,669
-12,481 Reduced 18.43%
55,248 $180,000
Q4 2023

Feb 14, 2024

SELL
$1.47 - $6.06 $326,442 - $1.35 Million
-222,070 Reduced 76.63%
67,729 $237,000
Q3 2023

Nov 14, 2023

BUY
$6.11 - $8.16 $822,717 - $1.1 Million
134,651 Added 86.79%
289,799 $1.94 Million
Q2 2023

Aug 14, 2023

SELL
$7.11 - $11.89 $235,305 - $393,499
-33,095 Reduced 17.58%
155,148 $1.3 Million
Q1 2023

May 15, 2023

SELL
$5.77 - $9.93 $3.01 Million - $5.18 Million
-521,910 Reduced 73.49%
188,243 $1.87 Million
Q4 2022

Feb 14, 2023

SELL
$5.08 - $7.09 $4.85 Million - $6.76 Million
-953,975 Reduced 57.33%
710,153 $4.94 Million
Q3 2022

Nov 14, 2022

SELL
$3.8 - $7.74 $2.49 Million - $5.06 Million
-654,050 Reduced 28.21%
1,664,128 $8.89 Million
Q2 2022

Aug 15, 2022

SELL
$2.43 - $4.85 $392,099 - $782,586
-161,358 Reduced 6.51%
2,318,178 $9.25 Million
Q1 2022

May 16, 2022

BUY
$3.25 - $5.17 $7.12 Million - $11.3 Million
2,190,919 Added 759.11%
2,479,536 $11 Million
Q4 2021

Feb 14, 2022

BUY
$3.5 - $9.63 $841,694 - $2.32 Million
240,484 Added 499.62%
288,617 $1.15 Million
Q3 2021

Nov 15, 2021

BUY
$7.94 - $11.31 $159,244 - $226,833
20,056 Added 71.43%
48,133 $423,000
Q2 2021

Aug 16, 2021

SELL
$10.44 - $14.85 $2.39 Million - $3.41 Million
-229,315 Reduced 89.09%
28,077 $318,000
Q1 2021

May 17, 2021

SELL
$6.53 - $14.42 $6.98 Million - $15.4 Million
-1,068,295 Reduced 80.58%
257,392 $3.06 Million
Q4 2020

Feb 16, 2021

BUY
$6.31 - $8.13 $1.87 Million - $2.41 Million
296,868 Added 28.86%
1,325,687 $9.09 Million
Q3 2020

Nov 16, 2020

BUY
$4.0 - $7.53 $3.9 Million - $7.35 Million
975,512 Added 1829.99%
1,028,819 $7.62 Million
Q2 2020

Aug 14, 2020

BUY
$1.97 - $5.05 $29,748 - $76,260
15,101 Added 39.53%
53,307 $223,000
Q1 2020

May 15, 2020

BUY
$1.62 - $6.4 $14,325 - $56,595
8,843 Added 30.12%
38,206 $95,000
Q4 2019

Feb 14, 2020

BUY
$4.73 - $7.98 $57,460 - $96,941
12,148 Added 70.57%
29,363 $171,000
Q3 2019

Nov 14, 2019

BUY
$4.41 - $6.12 $25,622 - $35,557
5,810 Added 50.94%
17,215 $90,000
Q2 2019

Aug 14, 2019

SELL
$6.0 - $9.0 $129,018 - $193,527
-21,503 Reduced 65.34%
11,405 $68,000
Q1 2019

May 15, 2019

BUY
$7.14 - $9.85 $142,514 - $196,606
19,960 Added 154.16%
32,908 $0
Q4 2018

Feb 14, 2019

BUY
$7.26 - $13.29 $11,173 - $20,453
1,539 Added 13.49%
12,948 $107,000
Q2 2018

Aug 10, 2018

BUY
$6.95 - $9.18 $1,105 - $1,459
159 Added 1.41%
11,409 $0
Q1 2018

May 11, 2018

BUY
$6.55 - $8.9 $73,687 - $100,125
11,250 New
11,250 $84,000

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $279M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.